Improving Safety of Preemptive Therapy with Oral Valganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation

Table 2

Patient cohorts of preemptive therapy for CMV viremias.

	Cohort 1 (1996–2006)			Cohort 2 (2007–2011)
	VGC	Non-VGC	P	VGC	Non-VGC	P
N patients	79	90	—	48	70	—
N viremias	165	147	—	67	135	—
Gender
Female	.44	.44	n.s.	.50	.47	n.s.
Male	.56	.56		.50	.53
Age
Median	50	43	<0.001	53	56	n.s.
Range	18–68	18–65		20–67	19–72
Diagnosis
Nonmalignant	.03	.00	n.s.	.03	.04	n.s.
Chronic malignancy	.24	.26		.17	.32
Acute malignancy	.73	.74		.80	.64
Disease risk
Standard	.29	.47	<0.05	.11	.23	n.s.
Advanced	.71	.53		.89	.77
Donor
Matched related	.28	.43	n.s.	.25	.21	n.s.
Matched unrelated	.68	.52		.44	.53
Mismatched	.04	.05		.31	.26
CMV
R−/D−, R−/D+, R+/D+	.51	.67	<0.05	.69	.70	n.s.
R+/D−	.49	.33		.31	.30
Conditioning
Reduced intensity	.65	.30	<0.001	.83	.79	n.s.
Myeloablative	.35	.70		.17	.21
T cell depletion
None	.11	.40		.06	.08	n.s.
In vivo (ATG)	.84	.44	<0.001	.94	.92
In vitro	.05	.16		.00	.00